IP Library Granted Patent US 8,575,102
Granted Patent B2
US 8,575,102 · App. 13/057,042 · Granted Nov 5, 2013

Conjugates having a releasable linkage

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,102
App. No.
13/057,042
Granted
Nov 5, 2013
Kind
B2
Abstract

The present invention provides conjugates encompassed by the following structure, wherein: D is a residue of an active agent bearing at least one amino group; and PEG-m is a methoxy end-capped poly(ethylene glycol), and further wherein the active agent is a coagulation factor having a molecular weight of greater than 100 kDa. Methods of making conjugates, and methods for administering conjugates, are also provided.

Claims (12)

1. A compound having the following structure:

wherein:

D is a residue of an active agent bearing at least one amino group; and;

PEG-m is a methoxy end-capped poly(ethylene glycol), and further wherein the active agent is a coagulation factor having a molecular weight of greater than 100 kDa.

2. The compound of claim 1 , wherein the coagulation factor is Factor VIII.

3. The compound of claim 2 , wherein the coagulation factor is a recombinantly synthesized coagulation factor of human origin.

4. The compound of claim 1 , wherein the poly(ethylene glycol) has a weight-average molecular weight of between 10,000 Daltons to 85,000 Daltons.

5. The compound of claim 4 , wherein the poly(ethylene glycol) has a weight-average molecular weight of between 20,000 and 50,000 Daltons.

6. The compound of claim 1 , wherein the poly(ethylene glycol) has between about 20 to 2000 monomeric repeats.

7. The compound of claim 6 , wherein the poly(ethylene glycol) has between about 100 to 1000 monomeric repeats.

8. A composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

9. A method of treatment comprising administering a composition of claim 8 to a subject in need thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2011
From: CULBERTSON, SEAN M.; MCMANUS, SAMUEL P.; BOSSARD, MARY J.
To: NEKTAR THERAPEUTICS
Reel/Frame 026192/0769 →